📈 Jumpstart Signal Watchlist — September 09, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $13.03 is 8% below 3yr high $14.14 · ⏳ SMA200 $6.67 (current price $13.03 is above) · 💰 Market Cap $735M
- PAYS passed all filters and shows favorable conditions.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (16.5%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage).
✅ Paysign Targets $117M Revenue as Patient-Affordability Business Surges — MarketBeat.
🤖 Paysign’s patient-affordability segment reportedly grew more than 85% in the first half, with full-year revenue expected to reach about $60 million and total company revenue targeted at up to $117 million. The strong segment growth and revenue outlook are positive for the stock.
✅ Paysign: Growth In Both Segments, But Guidance Implies Lower H2 ... — Seeking Alpha.
🤖 The article reports Q2 revenue growth of 48.1% to $28.3 million, an EPS beat, and raised 2026 revenue guidance of $114 million to $117 million. Although the outlook implies lower second-half earnings, the results and guidance increase are overall positive.
❌ Paysign (NASDAQ:PAYS) Shares Down 5.3% - MarketBeat — MarketBeat.
🤖 The article focuses on a 5.3% share-price decline and notes substantial recent insider selling. Those factors weigh negatively, despite the company’s prior quarterly earnings beat and continued Buy consensus.
❌ Paysign (NASDAQ:PAYS) Stock Rating Lowered by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen lowered Paysign from Strong Buy to Buy. While the broader analyst consensus remains Buy, the downgrade represents a negative analyst-rating catalyst.
⚪️ Bank of America Corp DE Grows Stock Position in Paysign, Inc. $PAYS — MarketBeat.
🤖 This article reports a routine institutional ownership increase by Bank of America. Under the classification rules, the backward-looking filing is neutral and is not treated as a directional catalyst.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $10.81 is 18% below 3yr high $13.11 · ⏳ SMA200 $8.56 (current price $10.81 is above) · 💰 Market Cap $1.8B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages — MarketBeat.
🤖 The article reports a Moderate Buy consensus from eight analysts and an average 12-month price target of $21.57 versus a recent share price of $11.39. It also notes that Vir’s quarterly EPS and revenue exceeded consensus estimates.
✅ Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week High - Should You Buy? — MarketBeat.
🤖 Vir shares reached a new 52-week high of $11.74. The article attributes the favorable backdrop partly to quarterly EPS and revenue beating expectations and cites a Moderate Buy analyst consensus with a substantially higher average price target.
✅ Vir Biotechnology stock hits 52-week high at 11.66 USD — Investing.com.
🤖 The article highlights Vir’s 52-week high and an 81% year-to-date return. It also cites improved cash reserves following an Astellas collaboration payment, a return to net income, fully enrolled Phase 3 hepatitis D programs, and H.C. Wainwright’s reiterated Buy rating.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: MISTRAS Group provides technology-enabled industrial asset integrity and asset protection solutions, including non-destructive testing, inspection, monitoring, and engineering services. It also offers related testing products, systems, and software for critical infrastructure and industrial assets.
- 🎯 At/above 3yr high $19.98 (current $19.98) · ⏳ SMA200 $15.75 (current price $19.98 is above) · 💰 Market Cap $636M
- MG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 130% (>20%); Low LT D/E 0.72 (<1.0); PEG ratio 0.19 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (7.3%)
- 🔔 Strong above EMA50 (12.0%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ MISTRAS Group Accelerates AI and Digital Innovation Strategy — Yahoo Finance.
🤖 MISTRAS announced an accelerated enterprise AI strategy and appointed an executive director of AI to scale digital capabilities. The initiative could strengthen its technology-enabled asset-integrity offering and create longer-term growth opportunities.
✅ Mistras Group (NYSE:MG) Hits New 1-Year High - Time to Buy? — MarketBeat.
🤖 MG reached a new 52-week high after its quarterly EPS and revenue exceeded consensus expectations. While the cited overall analyst consensus remained Hold, the reported operating performance and price momentum are positive signals.
❌ Sidoti Issues Negative Estimate for Mistras Group Earnings — MarketBeat.
🤖 Sidoti reduced its third-quarter 2026 EPS forecast to $0.38 from $0.42. Although the article noted MISTRAS's recent earnings and revenue beat, the near-term analyst estimate cut is negative.
🍭 Bonus (B): 0/10 — Engineering Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $58.33 is 1% below 3yr high $59.13 · ⏳ SMA200 $47.65 (current price $58.33 is above) · 💰 Market Cap $14.5B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Exelixis at Citigroup summit: building a second growth engine — Investing.com.
🤖 Management highlighted continued CABOMETYX market-share gains and positioned zanzalintinib as a potential second growth franchise with a projected $5 billion addressable market. The update also noted development risk following a frontline kidney-cancer setback, but the overall business-development message was constructive.
✅ Exelixis at Wells Fargo conference: zanzalintinib takes center stage — Investing.com.
🤖 Exelixis discussed preparing zanzalintinib for a potential colorectal-cancer launch pending FDA approval and expanding development across additional tumor types. The prospective new product franchise and continued CABOMETYX cash generation are positive catalysts, although approval remains contingent.
⚪️ Exelixis, Inc. (NASDAQ:EXEL) Sets New 12-Month High - Still a Buy? — MarketBeat.
🤖 The article noted a new 52-week high and an EPS beat, but also reported revenue below consensus and a Hold analyst consensus with a $50.07 average target below the then-current share price. Those offsetting signals make the overall implication neutral.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $58.90 is 2% below 3yr high $59.82 · ⏳ SMA200 $33.36 (current price $58.90 is above) · 💰 Market Cap $78.2B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.08 (<1.5).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (9.8%)
- 🔔 Strong above EMA50 (16.3%)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Hewlett Packard Enterprise's (HPE) "Buy" Rating Reiterated at Argus — MarketBeat.
🤖 Argus reiterated its Buy rating and assigned a $70 price target, citing strong fiscal third-quarter results, raised guidance, and demand for AI and networking products. Component shortages remain a risk, but the analyst action is favorable for HPE.
✅ HPE CEO on AI boom: 'Customers are buying everything' — Yahoo Finance.
🤖 HPE reported fiscal third-quarter revenue of $12.21 billion, up 34% year over year, and adjusted EPS of $1.11, while raising its fiscal 2027 revenue-growth outlook to 13%–17%. The CEO's comments indicate exceptionally strong AI-related demand.
❌ Hewlett Packard Enterprise Trading Down 5.1% on Analyst Downgrade — MarketBeat.
🤖 HPE shares fell 5.1% after UBS cut its price target from $65 to $59 and maintained a Neutral rating; Wells Fargo also reduced its target. Investors remain concerned that memory, CPU, and other component shortages could delay deliveries and pressure margins despite strong results and higher guidance.
❌ Hewlett Packard Enterprise Falls 5% as Supply Constraints Overshadow Raised Guidance, Super Micro Slips, Dell Holds Steady — Yahoo Finance.
🤖 HPE stock declined about 5% even after the company raised fiscal 2026 revenue-growth guidance to 34%–37% and reported strong third-quarter results. Supply constraints affecting memory, CPUs, and drives are limiting the company's ability to fulfill orders.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: ADM (Archer Daniels Midland Company) is a global agricultural processing and nutrition company that purchases crops from farmers, transports them through its logistics network, and transforms them into food, animal feed, industrial, and biofuel products.
- 🎯 Current $86.55 is 1% below 3yr high $87.32 · ⏳ SMA200 $72.07 (current price $86.55 is above) · 💰 Market Cap $42.0B
- ADM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (12.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 316% (>20%); Low LT D/E 0.32 (<1.0); PEG ratio 0.07 (<1.5).
⏰ Entry (E): 9/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ ADM at Barclays consumer conference: growth, costs and colors — Investing.com.
🤖 ADM highlighted stronger execution, improved cash generation, and favorable biofuels and nutrition trends. The company reportedly raised full-year adjusted EPS guidance to $5.15–$5.60, which is a positive catalyst for the stock.
✅ ADM (ADM) Up 10.1% Since Last Earnings Report: Can It Continue? — Yahoo Finance.
🤖 The article notes that ADM posted second-quarter 2026 adjusted earnings of $1.84 per share, up 98% year over year. The strong earnings growth and subsequent 10.1% share-price gain support a positive assessment, although the article questions whether the momentum can continue.
⚪️ Archer Daniels Midland (NYSE:ADM) Cut to "Buy" at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded ADM from strong buy to buy. The revised rating remains favorable but represents a modest reduction in bullishness, making the direct stock-price implication mixed to neutral.
🍭 Bonus (B): 0/10 — Food & Kindred Products

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.18 is 4% below 3yr high $35.53 · ⏳ SMA200 $25.26 (current price $34.18 is above) · 💰 Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (8.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Concentra at Wells Fargo 21st Annual Healthcare Conference: succession and growth — Investing.com.
🤖 Management highlighted steady operating momentum, margin gains, leverage below its 3x target, and more than 20% organic growth in its onsite occupational-health business. The company also described its Select Medical separation as nearly complete, though it remained cautious on the outlook.
✅ Concentra Group Holdings Parent (NYSE:CON) Upgraded by Zacks Research to "Strong-Buy" Rating — MarketBeat.
🤖 Zacks upgraded Concentra to Strong Buy from Hold. The article also cites second-quarter EPS and revenue above consensus and a broader Buy analyst consensus, which are supportive factors for the shares.
⚪️ Concentra Appoints Tanner Newton Chief Financial Officer — Yahoo Finance.
🤖 Concentra appointed Tanner Newton as CFO effective November 1 as part of its previously outlined leadership succession. The announcement does not report a material change in operating outlook or financial performance.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: # RingCentral, Inc. (RNG) RingCentral is a cloud-based business communications platform that provides unified communications, contact center solutions, workforce engagement management, video collaboration, and messaging services to over 500,000 businesses.
- 🎯 Current $69.64 is 9% below 3yr high $76.36 · ⏳ SMA200 $40.14 (current price $69.64 is above) · 💰 Market Cap $2.6B
- RNG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 221% (>20%); PEG ratio 0.25 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (17.6%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (60) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ RingCentral (RNG) Stock Fair Value Rises After Analysts Back Stronger Margins And AI Upsell — Yahoo Finance.
🤖 This article highlights higher analyst fair value estimates and price targets, including bullish views from RBC Capital and Oppenheimer. The tone is constructive for RNG because it points to improving margins, AI-driven upsell potential, and stronger valuation support.
✅ RingCentral (NYSE:RNG) Raised to "Moderate Buy" at Royal Bank of Canada — MarketBeat.
🤖 The article reports an upgrade to a higher recommendation from RBC, which is generally supportive for the stock. It also references RingCentral’s recent earnings beat and guidance, reinforcing the positive analyst backdrop.
⚪️ RingCentral to Present at Goldman Sachs and Piper Sandler Conferences — Yahoo Finance.
🤖 This is a routine investor-relations announcement about upcoming conference presentations, with no new financial results or guidance. It is company-specific but not a clear catalyst for the stock.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)